AcelRx: We Would Be Buyers Ahead Of The PDUFA, Says Roth Capital
In a research report released yesterday, Roth Capital analyst Ed Arce reiterated a Buy rating on AcelRx Pharmaceuticals Inc. (ACRX) with a price target of $22.00, following yesterday’s news that ACRX’s EU marketing partner, Grunenthal, submitted a Marketing Authorization Application to the European Medicines Authority for ZALVISO for the management of moderate to severe acute pain in adult patients in a medically supervised environment.
Arce wrote, “Grunenthal filed Zalviso with the EMA, triggering a $5M milestone to AcelRx. We expect a mid-2015 approval and peak EU sales of $260M, with royalties to AcelRx of $40M. With Zalviso’s likely US approval this month and the initiation of a pivotal P3 trial of ARX-04 this year, we believe AcelRx continues to execute well, creating further shareholder value. We would be buyers ahead of the PDUFA”. The analyst added, “With multiple near-term catalysts, including the expected US commercial launch of Zalviso in 1Q15, we view ACRX shares as a strong, long-term growth holding within the sector. We recommend establishing or adding positions in ACRX shares ahead of the PDUFA date”.
According to TipRanks.com, analyst Ed Arce currently has an average return of 59.2% and a 67% success rate. Arce has a 16.8% average return when recommending ACRX is ranked #112 out of 3162 analysts.